We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 24, 2020

Applicability of FDA Labeling for Dapagliflozin to Patients With HFrEF in US Clinical Practice

JAMA Cardiology


Additional Info

JAMA Cardiology
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With The Guidelines–Heart Failure (GWTG-HF) Registry
JAMA Cardiol 2020 Nov 13;[EPub Ahead of Print], M Vaduganathan, SJ Greene, S Zhang, M Grau-Sepulveda, AD DeVore, J Butler, PA Heidenreich, JC Huang, MM Kittleson, KE Joynt Maddox, JJ McDermott, AT Owens, PN Peterson, SD Solomon, O Vardeny, CW Yancy, GC Fonarow

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading